• 1
    Huggins C, Hodges CV. Studies on prostate cancer. Effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293297.
  • 2
    Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321:419424.
  • 3
    Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993; 149:607609.
  • 4
    Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11:15661572.
  • 5
    Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for antiandrogen withdrawal syndrome. Urology 1994; 43:408410.
  • 6
    Bissada NK, Kaczmarek AT. Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol. J Urol 1995; 153:19441945.
  • 7
    Dawson NA, McLeod DG. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 1995; 153: 19461947.
  • 8
    Huggins C, Scott WW. Bilateral adrenalectomy of prostatic cancer; clinical features and urinary excretion of 17-ketosteroids and estrogens. Ann Surg 1945; 122:10311041.
  • 9
    Stahl F, Schnorr D, Bar CM, Frohlich G, Dorner G. Suppression of plasma androgen levels with a combination therapy of depot-estrogen (Turisteron) and dexametha-sone in patients with prostatic cancer. Exp Clin Endocrinol 1989; 94:239243.
  • 10
    Williams G, Asopa R, Abel PD, Smith C. Pituitary adrenal and gonadal endocrine suppression for the primary treatment of prostate cancer. Br J Urol 1990; 65:504508.
  • 11
    Japanese Urological Association and the Japanese Pathological Society General rules for clinical and pathological studies on prostatic cancer. 2nd ed. Tokyo : Kanehara, 1992: 9106.
  • 12
    Nishiyama T, Terunuma M. Prostate specific antigen and prostate acid phosphatase declines after estramustine phosphate withdrawal: a case report. Int J Urol 1994; 1:355356.
  • 13
    Akakura K, Akimoto S, Ohkd T, Shimazaki J. Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate. Urology 1995; 45:700704.
  • 14
    Sekido N, Kawai K, Akaza H, Koiso K. Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer. Jpn J Clin Oncol 1995; 25:164167.
  • 15
    Scher HI, Zhang ZF, Nanus D, Kelly WK. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology 1996; 47:6169.
  • 16
    Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990; 173:534540.
  • 17
    Kirschenbaum A, Ren M, Levine AC. Enhanced androgen sensitivity in serum-free medium of a subline of the LNCaP human prostate cancer cell line. Steroids 1993; 58:439444.
  • 18
    Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995; 46:2, 142–148.
  • 19
    Storlie JA, Buckner JC, Wiseman JA, Burch PA, Hartmann LC, Richardson RL. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostatic carcinoma. Cancer 1995; 76:96100.